Find Paper, Faster
Example:10.1021/acsami.1c06204 or Chem. Rev., 2007, 107, 2411-2502
CDK4/6 inhibitors in breast cancer: spotting the difference
Nature Medicine  (IF53.44),  Pub Date : 2021-11-08, DOI: 10.1038/s41591-021-01570-9
Jose Manuel Perez-Garcia, Javier Cortes, Antonio Llombart-Cussac

A phase 3 study with dalpiciclib reinforces the efficacy of CDK4/6 inhibitors in select patients with metastatic breast cancer; with several such inhibitors available, more evidence is needed to help guide treatment decisions.